viewWilliam Stilley, CEO of Adial Pharmaceuticals (NASDAQ: ADIL) sits down with BAF host Michelle Griego to discuss the company’s lead asset, AD04, as a potential genetically targeted treatment for alcohol and opioid use disorder.
viewWilliam Stilley, President and Chief Executive Officer, on the KSWB-TV FOX 5 Morning News in San Diego to discussing AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder
viewAdial’s Dr. Bankole Johnson Featured on The Doctors Channel discussing medicinal approaches to alcohol use disorder.
viewAdial Pharmaceuticals’ Chairman, Professor Bankole Johnson, sits down with The Doctor’s Channel to speak about Alcohol Use Disorder and the massive toll it exacts on global health.
viewAdial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials of AD04 for the Treatment of Alcohol Use Disorder
viewAlcoholism: Is there a medicinal solution on the horizon? EHealth Radio invited Adial’s CEO, William Stilley, for an interview. Listen to the interview to learn more!
viewDebunking the Myths About Alcoholism & Addiction, w/ Professor Bankole Johnson of the U of Maryland and HBO’s “Addiction” | EDB 73
viewTreating Addiction Through Neuroscience Breakthroughs, with Prof. Bankole Johnson of the University of Maryland School of Medicine | EDB 72
viewLeading internet business program CEO Money Interviews Adial CEO. Adial Pharmaceuticals is developing a genetically targeted treatment for alcohol addiction.
